-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 31, Xinlitai announced that it had recently received the "Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, and agreed to carry out clinical trials for SAL0104 capsules.
SAL0104 capsule is a coagulation factor XIa inhibitor, and its intended development indication is the prevention and treatment of thrombotic diseases.